Login to Your Account



Back from bankruptcy brink, Kalobios seeks 'a change for good'

By Marie Powers
News Editor

Friday, July 1, 2016

Describing Kalobios Pharmaceuticals Inc. as "the little engine that could," Cameron Durrant, chairman and CEO, said the company's emergence from bankruptcy opened a new chapter that repositioned newly acquired asset benznidazole as lead compound in its neglected and rare disease pipeline and provided exit equity financing of $11 million to restart its development engines.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription